Uwe Platzbecker, MD, University of Leipzig, Leipzig, Germany, discusses novel treatments for cytopenia in myelodysplastic syndromes (MDS) at ESH MDS 2021. In particular, he highlights anti-inflammatory treatments in the early stages of development and a Phase II/III trial (NCT02598661) evaluating imetelstat in patients with low- or intermediate-risk MDS. This interview took place during the 2021 European School of Hematology (ESH) 7th Translational Research E-Conference on Myelodysplastic Syndromes.